Onasemnogene Abeparvovec: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Onasemnogene Abeparvovec. Educational only — not medical advice.
Labeled uses
ITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene.
Source: FDA labeling via NIH DailyMed (set ab2e1c6c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.